We are live on ! Find out more
N

Nuveen Portfolio holdings

AUM $369B
1-Year Est. Return 31.66%
This Fund
S&P 500
This Quarter Est. Return
+10%
1 Year Est. Return
+31.66%
3 Year Est. Return
+110.02%
5 Year Est. Return
+148.02%
10 Year Est. Return
+492.84%
AUM
$264B
AUM Growth
+$16.6B
Cap. Flow
-$3.28B
Cap. Flow %
-1.24%
Top 10 Hldgs %
18.75%
Holding
3,331
New
118
Increased
1,090
Reduced
1,840
Closed
95

Top Sells

Rank Stock Value
1
CSCO icon
Cisco
CSCO
+$474M
2
CELG
Celgene Corp
CELG
+$421M
3
AVGO icon
Broadcom
AVGO
+$411M
4
NFLX icon
Netflix
NFLX
+$387M
5
AAPL icon
Apple
AAPL
+$372M

Sector Composition

Rank Sector Weight
1 Technology 20.51%
2 Financials 14.64%
3 Healthcare 13.3%
4 Consumer Discretionary 10.29%
5 Communication Services 9.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FDBC icon
3001
Fidelity D&D Bancorp
FDBC
$317M
$305K ﹤0.01%
4,898
-3,231
-40% -$210K
LCUT icon
3002
Lifetime Brands
LCUT
$211M
$305K ﹤0.01%
43,918
-18,300
-29% -$132K
SBBX
3003
DELISTED
SB One Bancorp Common Stock
SBBX
$305K ﹤0.01%
12,240
ING icon
3004
ING
ING
$102B
$304K ﹤0.01%
+25,200
New +$289K
LJPC
3005
DELISTED
La Jolla Pharmaceutical Company
LJPC
$303K ﹤0.01%
77,178
-6,575
-8% -$38.8K
ESQ icon
3006
Esquire Financial Holdings
ESQ
$1.14B
$301K ﹤0.01%
+11,563
New +$283K
III icon
3007
Information Services Group
III
$251M
$301K ﹤0.01%
119,057
OVBC icon
3008
Ohio Valley Banc Corp
OVBC
$205M
$300K ﹤0.01%
7,581
-6,750
-47% -$253K
STRO icon
3009
Sutro Biopharma
STRO
$421M
$300K ﹤0.01%
2,724
-99
-4% -$10.2K
SLDB icon
3010
Solid Biosciences
SLDB
$900M
$299K ﹤0.01%
4,471
-1,028
-19% -$113K
IGMS
3011
DELISTED
IGM Biosciences
IGMS
$298K ﹤0.01%
+7,818
New +$196K
TYME
3012
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$298K ﹤0.01%
212,879
-41,685
-16% -$50.6K
PYX
3013
DELISTED
Pyxus International, Inc.
PYX
$296K ﹤0.01%
33,134
-1,552
-4% -$15K
MPB icon
3014
Mid Penn Bancorp
MPB
$952M
$294K ﹤0.01%
10,212
AMPY icon
3015
Amplify Energy
AMPY
$166M
$293K ﹤0.01%
44,259
-372,100
-89% -$2.4M
CHMG icon
3016
Chemung Financial Corp
CHMG
$392M
$293K ﹤0.01%
6,894
-5,772
-46% -$253K
EML icon
3017
Eastern Company
EML
$150M
$293K ﹤0.01%
9,610
-9,824
-51% -$275K
BPMP
3018
DELISTED
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
$293K ﹤0.01%
18,779
-1,958
-9% -$29K
YELL
3019
DELISTED
Yellow Corporation Common Stock
YELL
$292K ﹤0.01%
114,480
-130,177
-53% -$447K
ALCO icon
3020
Alico
ALCO
$283M
$287K ﹤0.01%
8,014
-6,116
-43% -$206K
AVXL icon
3021
Anavex Life Sciences
AVXL
$310M
$285K ﹤0.01%
110,195
PRVL
3022
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$282K ﹤0.01%
17,831
-6,576
-27% -$83.9K
BBCP icon
3023
Concrete Pumping Holdings
BBCP
$491M
$279K ﹤0.01%
50,971
-16,205
-24% -$66K
HBT icon
3024
HBT Financial
HBT
$1.32B
$276K ﹤0.01%
+14,539
New +$248K
PEBK icon
3025
Peoples Bancorp of North Carolina
PEBK
$229M
$276K ﹤0.01%
8,406
-9,147
-52% -$279K

Similar funds

Nuveen's Q4 2019 Portfolio in Review

As of Q4 2019, Nuveen held 3,331 positions worth $264B, up 6.7% from $247B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Nuveen's Q4 2019 filing shows 118 new, 1,090 increased, 1,840 reduced and 95 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B. The largest sale was Cisco, an estimated $474M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.

  • Nuveen's largest Q4 2019 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 8,077,161 shares worth $1.03B.
  • Nuveen added most to Bristol-Myers Squibb in Q4 2019, an estimated $649M increase.
  • Nuveen's biggest Q4 2019 reduction was Cisco, cutting an estimated $474M.
  • Nuveen fully exited Celgene Corp in Q4 2019, selling an estimated $421M.
  • Nuveen's ten largest holdings make up 19% of its $264B portfolio in Q4 2019.
  • Nuveen opened 118 new positions and closed 95 in Q4 2019.
  • Nuveen's portfolio value rose 6.7% quarter-over-quarter to $264B.

Based on Nuveen's 13F filing for Q4 2019, filed 14 Feb 2020.